Pharmacogenetics and nicotine addiction treatment.
This review focuses on the current status of, and future directions for, pharmacogenetic research on nicotine dependence and smoking cessation treatment. Pharmacological treatment involving nicotine replacement therapy and bupropion for nicotine addiction and smoking cessation has been shown to be efficacious when provided in combination with behavioral support. Cessation rates remain somewhat modest, however, and one possibility is that success rates may be enhanced by offering treatments tailored to an individual's genotype. Nonetheless, research on this issue remains in its infancy, and although the scope for individualized treatment tailored to genotype is promising, there are substantial practical, ethical and social considerations that must be addressed before such research is translated into clinical practice.
Munafò
Marcus R
MR
University of Bristol, Department of Experimental Psychology, Bristol BS8 ITN, UK. marcus.munafo@bris.ac.uk
Shields
Alexandra E
AE
Berrettini
Wade H
WH
Patterson
Freda
F
Lerman
Caryn
C
D016642:Bupropion / Q000627:therapeutic use; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics / Q000941:ethics / Q000379:methods / Q000639:trends*; D016540:Smoking Cessation; D014029:Tobacco Use Disorder / Q000188:drug therapy* / Q000235:genetics
D016642:Bupropion